Parathyroid Hormone Drives Pulmonary Hypertension Through a Newly Identified Receptor Pathway
New research links elevated PTH levels to pulmonary hypertension progression, identifying PTH1R signaling as a promising therapeutic target.
Summary
Researchers at Juntendo University discovered that parathyroid hormone (PTH) — best known for regulating calcium — also contributes to pulmonary hypertension (PH). In clinical data, serum PTH levels correlated with pulmonary artery pressure, with a cutoff of 46 pg/mL predicting PH with high specificity. Animal experiments showed PTH worsened right ventricular hypertrophy, while parathyroidectomy reduced it. Lab studies revealed that hypoxia activates HIF1α, which upregulates the PTH receptor (PTH1R), creating a feedback loop that drives smooth muscle cell proliferation and vascular remodeling via β-arrestin-ERK signaling. These findings position PTH1R as a novel therapeutic target in pulmonary hypertension.
Detailed Summary
Pulmonary hypertension is a progressive and life-threatening condition marked by elevated pulmonary artery pressure that ultimately leads to right heart failure. Despite advances in treatment, its molecular drivers remain incompletely understood. This study investigates a surprising contributor: parathyroid hormone (PTH), a calcium-regulating peptide with underappreciated cardiovascular effects.
Researchers measured serum PTH in patients undergoing right heart catheterization for suspected PH. They found a statistically significant association between PTH levels and both mean pulmonary artery pressure and pulmonary vascular resistance. A PTH cutoff of 46 pg/mL predicted PH with 68.2% sensitivity and 100% specificity — a striking level of precision that warrants further validation.
Animal models reinforced the clinical signal. In hypoxia-induced PH mice and Sugen/hypoxia rats, exogenous PTH worsened right ventricular hypertrophy and elevated right ventricular systolic pressure. Critically, parathyroidectomy — surgical removal of the parathyroid glands — attenuated these effects and reduced pulmonary vascular remodeling, suggesting PTH is not merely a bystander but an active pathological driver.
The mechanistic core of the study reveals a hypoxia-PTH axis: HIF1α, the master transcription factor activated under low oxygen, upregulates PTH1R expression in the lungs. PTH then acts through PTH1R to activate β-arrestin-ERK signaling, stimulating proliferation and migration of pulmonary artery smooth muscle cells — hallmarks of vascular remodeling in PH. Knockdown of PTH1R in lung tissue ameliorated PH in both rodent models.
These findings open a new therapeutic avenue, as PTH1R is a druggable target. However, the clinical data are observational, the specificity figure requires replication in larger cohorts, and whether PTH elevation is a cause or consequence of PH in humans needs further investigation.
Key Findings
- Serum PTH correlated with pulmonary artery pressure; a 46 pg/mL cutoff predicted PH with 100% specificity.
- PTH administration worsened right ventricular hypertrophy and pressure in two independent animal PH models.
- Parathyroidectomy reduced pulmonary vascular remodeling and right ventricular hypertrophy in Sugen/hypoxia rats.
- HIF1α upregulates PTH1R under hypoxia, linking oxygen sensing to PTH-driven vascular remodeling.
- PTH promotes smooth muscle cell proliferation and migration via PTH1R-β-arrestin-ERK signaling axis.
Methodology
The study combined a clinical observational cohort (right heart catheterization patients) with two animal PH models (hypoxia-induced mice and Sugen/hypoxia rats) and in vitro experiments using human pulmonary artery smooth muscle cells. PTH1R knockdown and parathyroidectomy were used as loss-of-function approaches across models.
Study Limitations
The clinical association is observational and cannot establish causality; the 100% specificity figure is unusually high and must be replicated in larger, prospective cohorts. It remains unclear whether PTH elevation is a driver or a consequence of PH in humans. Rodent models do not fully recapitulate human pulmonary hypertension pathophysiology.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: